In a cohort of 54 melanoma patients receiving anti-PD-1 antibody monotherapy, non-responding patients had abundant expressions of immune gene markers such as TNFAIP3 (encoding A20) and TLR3 in tumors, which was associated with a dampened immune response [45]. Here, TLR3 is linked to melanoma.